Eli Lilly Zepbound beats high-dose Wegovy in head-to-head weight loss analysis

Eli Lilly reported that specific doses of Zepbound achieved greater weight loss than the high-dose version of Novo Nordisk's Wegovy in a comparative analysis. This is a competitive development in the GLP-1 market, potentially shifting physician prescribing and payer coverage decisions. The claim is based on company-reported data, not yet independently peer-reviewed.